SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

30 Jan 2025 Evaluate
The company's total revenue for the quarter ended December 2024 saw a slight change in the total revenue, having registered a total revenue of Rs. 11019.20 millions.Profit saw a slight increase of 14.67%to Rs. 2524.50  millions from Rs. 2201.50 millions.Operating profit for the quarter ended December 2024 rose to 3695.60 millions as compared to 3409.10 millions of corresponding quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 11019.20 10852.90 1.53 33081.00 30450.50 8.64 39711.20 34112.70 16.41
Other Income 332.30 137.30 142.02 1019.40 973.50 4.71 1164.80 1327.50 -12.26
PBIDT 3695.60 3409.10 8.40 10570.10 9750.80 8.40 12359.10 8320.30 48.54
Interest 24.80 23.60 5.08 39.30 53.80 -26.95 68.00 52.30 30.02
PBDT 3670.80 3385.50 8.43 10530.80 9697.00 8.60 12291.10 8268.00 48.66
Depreciation 349.30 334.10 4.55 1011.70 986.90 2.51 1321.60 1269.50 4.10
PBT 3321.50 3051.40 8.85 9519.10 8710.10 9.29 10969.50 6998.50 56.74
TAX 797.00 849.90 -6.22 2284.50 2264.60 0.88 2897.10 1411.30 105.28
Deferred Tax 33.20 30.50 8.85 95.20 87.10 9.30 121.30 -29.30 -513.99
PAT 2524.50 2201.50 14.67 7234.60 6445.50 12.24 8072.40 5587.20 44.48
Equity 250.70 252.70 -0.79 250.70 252.70 -0.79 252.70 252.70 0.00
PBIDTM(%) 33.54 31.41 6.77 31.95 32.02 -0.22 31.12 24.39 27.60

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×